A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Chronic Lymphocytic · Small-Cell Lymphoma · Lymphoma, Small Lymphocytic · CLL · SLL
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 735 (planned)
- Started
- Aug 8, 2023
- Main results expected
- Jun 1, 2032
- Fully finished
- Jul 1, 2035
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Measured over: Up to approximately 12 Weeks
Part 1: Number of Participants Experiencing Adverse Events (AEs)
Measured over: Up to approximately 28 months
Part 1: Number of Participants Discontinuing Study Treatment Due to AEs
Measured over: Up to approximately 25 months
Part 2: PFS per the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 71 months
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","statusModule"]}
Trial ID NCT05947851 · record last updated 2026-11-06 · checked 2026-11-09 15:42 UTC